Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
topharm.com

See what CB Insights has to offer

About TO Pharma

TO Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics based on its proprietary cannabinoid product platform in a number of FDA-regulated clinical indications and in select OTC markets.

TO Pharma Headquarter Location

2150 Cabot Blvd West Suite B

Langhorne, Pennsylvania, 19047,

United States

215-702-8550

Latest TO Pharma News

Sansera Engineering IPO, Zee Entertainment to Pharma Stocks - here are top Buzzing Stocks today

Sep 14, 2021

At 12:42 pm, the S&P BSE Sensex was trading with a gain of 200.99 points or 0.35% at 58,378.75 while the Nifty 50 index was trading 61.50 points or 0.35% higher at 17,416.80. Written By: Jitesh Kumar Jha Updated: Tue, Sep 14, 2021 12:59 pm RELATED NEWS Domestic equity markets were trading in a narrow range with modest gains on Tuesday’s noon deals. At 12:42 pm, the S&P BSE Sensex was trading with a gain of 200.99 points or 0.35% at 58,378.75 while the Nifty 50 index was trading 61.50 points or 0.35% higher at 17,416.80. Meanwhile, certain stocks were in action in either direction based on reports linked to them. Here is a list of few such stocks: See Zee Business Live TV Streaming Below: IPOs – 2 listings + 1 opening  Vijaya Diagnostic Center: The shares of the company debuted on the stock markets today at Rs 540 per share against the issue price of Rs 540 per share. Ami Organics: The shares of the Surat-based specialty chemical company Ami Organics debuted the share markets today at Rs 910 per share against the issue price of Rs 610 per share. Sansera Engineering IPO: The initial public offering (IPO) of the auto component manufacturer Sansera Engineering that opened for subscription today was subscribed 0.22 times by 12:23 pm. The public issue will be available for subscription till Thursday, September 16, 2021. The Rs 1,282.98 crore public issue is a 100 per cent Offer for Sale (OFS) of 17,244,328 equity shares by its existing shareholders and promoters. The company has a fixed price band of the IPO at Rs 734-744 per share. Retail investors looking forward to subscribing to Sansera Engineering’s IPO can place bids in the lot of 20 equity shares and multiples thereafter. Stocks in News Suryoday Small Finance Bank: Up 12.14%. The company in its clarification to news quoting merger talks between Clix Capital & Suryoday said we are unable to comment on media speculation and rumours. In its commentary, the company has said that at present, there is no such decision taken by the Board or any of its committees. Accordingly, we would be unable to comment upon the said News Article. RPP Infra Projects: Up 2.34%. The Board of Directors of RPP Infra Projects Ltd have approved the offer and issuance of 1.60 crores fully paid-up equity shares of the Company (Rights Equity Shares) for an amount not exceeding Rs 48.00 crores, by way of a rights issue (Rights Issue). The ratio of the rights issue is fixed as 3:5 (3 Rights Equity Shares for every 5 fully paid-up Equity Shares held by the eligible equity shareholders of our Company on the Record Date) at a price of Rs 30 per Rights Equity Share (including a premium of Rs. 20 per Rights Equity Share). KNR Constructions: Up 2.47%. The company is in receipt of a Letter of Acceptance for Hyderabad Growth Corridor Limited (HGCL) for widening of existing service roads from Nanakramguda to TSPA and Narsingi to Kollur and BT Overlay of Bitumen pavement from Gachibowli to Shamshabad of Outer Ring Road, Hyderabad, Telangana, worth Rs 312.8 crore on Bill of Quantities basis. The said project is to be completed within a period of 15 months from the date of signing of the Agreement. DCM Shriram: Up 1.16%. The Board of Directors of the company approved the proposal to acquire/buy 1,732,500 equity shares (50% stakes) of Shriram Axiall Pvt. Ltd. (SAPL) at Rs 137.40 per share from Axiall LLC. SAPL is a 50:50 JV between the Company and Axiall LLC, (USA). Infosys: Down 0.20%. The Board of Directors of the Company will meet on October 12 and 13, 2021 to approve and take on record the audited consolidated financial results of the Company and its subsidiaries for the quarter and half year ending September 30, 2021. It will also consider the declaration of interim dividend if any. Vedanta: Down 0.73%. Vedanta Resources Ltd (VRL) on Monday announced that the company has reduced its net debt by $30 crore in the first half of this fiscal and expects to further reduce its debt by $50 crore in the second half of FY'22. Amber Enterprises: Up 1.01%. The company has invested 100,000 USD in Amber Enterprises USA Inc. and has been allotted 100,000 common stocks at a par value of USD 1 per share. Post the allotment of shares, Amber Enterprises USA Inc. has now become Wholly Owned Subsidiary of Amber Enterprises India Limited w.e.f September 13, 2021. It will increase the footprints of Amber Enterprises India Limited in foreign countries along with export turnover. BLS International: Up 3.81%. BLS International partners with National Health Authority as a service provider to process Ayushman Bharat Cards across India. HAL: Up 1.91%. The company in its investor presentation released today said that it anticipates new orders for 15 LCH, 12 SU-30, HTT-40, LUH among others. Government’s push for Atmanirbhar Bharat and positive indigenisation list providing a boost to HAL’s Business. It has a strong order book position with prospects for further additions. First-quarter performance was affected due to the 2nd Wave of Covid-19. Expected to return to normalcy during the remaining period of the year. Laurus Labs: Up 1.56%. The company has today announced that development is underway based on an agreement launched in June 2021 between the Company, Unitaid and the Clinton Health Access Initiative (CHAI), to accelerate the development, commercialization, and registration of the best-in-class second-and third-line HIV treatment darunavir boosted with ritonavir (DRV/r) for children. Buzzing Stocks Yes Bank: Up 13.06%. Pharma Stocks: Moving up. Stocks like Ajanta Pharma – up 3.06%; Nectar Lifesciences – up 2.23%; Divi’s Laboratories – up 0.43%; Sequent Scientific – up 1.29%; Glenmark – up 0.96%; Cipla – up 0.33% and Abbott India – up 1.09% were trading higher. GST Council is likely to consider the reduction of GST rates on selected drugs from 12% to 5%. The council is likely to consider a reduction in GST rates on drugs like Itolizumab, posaconazole, infliximab, bamlanivimab & etesevimab, casirivimab & imdevimab, 2-deoxy-d-glucose and favipiravir. Packaging Stocks: Moving up. Stocks like Polyplex Corp – up 5.95%; Cosmo Films – 9.47%; Uflex – up 5.43% and Jindal Poly Films – up 5.59% were trading higher Rice Stocks: Moving up. Stocks like KRBL – up 2.15% and LT Foods – up 1.32% were trading higher.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing TO Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TO Pharma is included in 1 Expert Collection, including Cannabis.

C

Cannabis

3,602 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

TO Pharma Patents

TO Pharma has filed 4 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Cannabinoids
  • Designer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/28/2017

Cannabinoids, Designer drugs, Inflammations, Phenols, Autoimmune diseases

Application

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/28/2017

00/00/0000

00/00/0000

00/00/0000

Grant Date

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Cannabinoids, Designer drugs, Inflammations, Phenols, Autoimmune diseases

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Application

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.